BNT324

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Prostate CancerLung CancerMetastatic Castration-Resistant Prostate CancerAdvanced Lung Cancer

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

1

BNT324

BioNTech

Phase 3

22

Novantrone

Pfizer

Preclinical

53

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

25

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

16

Prednisone/prednisolone

Roche

Preclinical

37

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—9

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—10

Statin

Bristol-Myers Squibb

Preclinical

1Show 12 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Metastatic Castration-Resistant Prostate Cancer1 trial

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

Recruiting·BioNTech·Phase 3·NCT07365995·736 enrolled

Advanced Lung Cancer1 trial

A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer

Recruiting·BioNTech·Preclinical·NCT06892548·594 enrolled

Details

Drug Info

Related News